Tom 14, Nr 4 (2020)
Wybrane problemy kliniczne
Opublikowany online: 2020-07-30
Wyświetlenia strony
1944
Wyświetlenia/pobrania artykułu
1149
Profilaktyka, diagnostyka i leczenie martwicy kości szczęk związanej z lekami
1
, 1, 1, 1, 1
, 1, 1, 1, 1
Forum Medycyny Rodzinnej 2020;14(4):173-180.
Streszczenie
Martwica kości szczęk związana z lekami (MRONJ) to jednostka chorobowa, która powstaje
w wyniku działań niepożądanych leków antyresorpcyjnych lub antyangiogennych. Największy
wzrost ryzyka rozwoju MRONJ jest obserwowany wśród pacjentów onkologicznych leczonych
dożylnie dużymi dawkami bisfosfonianów przez okres dłuższy niż 2 lata.
Wśród chorych z grup ryzyka należy prowadzić działania profilaktyczne przed i w trakcie leczenia
lekami antyresorpcyjnymi oraz antyangiogennymi. Wykonuje się sanację jamy ustnej
oraz korektę wszelkich wypełnień i prac protetycznych. W przypadku wystąpienia MRONJ,
należy wdrożyć leczenie zachowawcze lub chirurgiczne, w zależności od nasilenia objawów.
Celem leczenia chirurgicznego jest usunięcie martwej tkanki oraz odpowiednie zaopatrzenie
rany. Leczenie powinno być interdyscyplinarne, aby zwiększyć jakość życia pacjentów.
Celem pracy była analiza doniesień naukowych dotyczących etiolo gii, diagnostyki i leczenia
pacjentów z martwicą kości szczęk oraz współpracy pomiędzy lekarzem dentystą
i lekarzem rodzinnym.
Słowa kluczowe: bisfosfonianyosteonekrozaMRONJ
Referencje
- American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc. 2006; 137(8): 1144–1150.
- Kim DW, Jung YS, Park HS, et al. Osteonecrosis of the jaw related to everolimus: a case report. Br J Oral Maxillofac Surg. 2013; 51(8): e302–e304.
- Ruggiero SL, Dodson TB, Fantasia J. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update and CTX. J Oral Maxillofac Surg. 2014; 72(10): 1938–1956.
- Rosella D, Papi P, Giardino R, et al. Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. J Int Soc Prev Community Dent. 2016; 6(2): 97–104.
- Abed HH, Al-Sahafi EN. The role of dental care providers in the management of patients prescribed bisphosphonates: brief clinical guidance. Gen Dent. 2018; 66(3): 18–24.
- Morris M, Cruickshank S. Bisphosphonate-related osteonecrosis of the jaw in cancer patients: Implications for nurses. Eur J Oncol Nurs. 2010; 14(3): 205–210.
- Kalra S, Jain V. Dental complications and management of patients on bisphosphonate therapy: A review article. J Oral Biol Craniofac Res. 2013; 3(1): 25–30.
- Lam DK, Sándor GK, Holmes HI, et al. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc. 2007; 73(5): 417–422. indexed in Pubmed: 17555652.
- Marx RE. Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws. History, etiology, prevention, and treatment. Quintessence Publishing Co Inc. 2007; 9–96.
- Mignogna MD, Sadile G, Leuci S. Drug-related osteonecrosis of the jaws: "Exposure, or not exposure: that is the question". Oral Surg Oral Med Oral Pathol Oral Radiol. 2012; 113(5): 704–705.
- Kaczmarzyk T, Babiuch K, Bołtacz-Rzepkowska E, et al. Rekomendacje Grupy Roboczej Polskiego Towarzystwa Stomatologicznego i Narodowego Programu Ochrony Antybiotyków w zakresie stosowania antybiotyków w stomatologii. Narodowy Instytut Leków, Warszawa 2019.
- Haworth AE, Webb J. Skeletal complications of bisphosphonate use: what the radiologist should know. Br J Radiol. 2012; 85(1018): 1333–1342.
- Otto S, Ristow O, Pache C, et al. Fluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw: A prospective cohort study. J Craniomaxillofac Surg. 2016; 44(8): 1073–1080.
- Nonnenmühlen N, Burnic A, Bartella A, et al. Comparison of mucosal and mucoperiosteal wound cover for the treatment of medication-related osteonecrosis of the jaw lesions: a retrospective cohort study. Clin Oral Investig. 2019; 23(1): 351–359.
- Beth-Tasdogan NH, Mayer B, Hussein H, et al. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2017; 10: CD012432.
- Weber JB, Camilotti RS, Ponte ME. Efficacy of laser therapy in the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ): a systematic review. Lasers Med Sci. 2016; 31(6): 1261–1272.
- Kwon YD, Kim DY. Role of Teriparatide in Medication-Related Osteonecrosis of the Jaws (MRONJ). Dent J (Basel). 2016; 4(4).
- Jung J, Yoo HY, Kim GT, et al. Short-Term Teriparatide and Recombinant Human Bone Morphogenetic Protein-2 for Regenerative Approach to Medication-Related Osteonecrosis of the Jaw: A Preliminary Study. J Bone Miner Res. 2017; 32(12): 2445–2452.
- Gerard DA, Carlson ER, Gotcher JE, et al. Early inhibitory effects of zoledronic acid in tooth extraction sockets in dogs are negated by recombinant human bone morphogenetic protein. J Oral Maxillofac Surg. 2014; 72(1): 61–66.
- Epstein MS, Wicknick FW, Epstein JB, et al. Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 110(5): 593–596.
- Magremanne M, Reychler H. Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis. J Oral Maxillofac Surg. 2014; 72(2): 334–337.
- Owosho AA, Estilo CL, Huryn JM, et al. Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016; 122(4): 455–459.
- Ripamonti CI, Cislaghi E, Mariani L, et al. Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I-II study. Oral Oncol. 2011; 47(3): 185–190.
- Agrillo A, Filiaci F, Ramieri V, et al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): 5 year experience in the treatment of 131 cases with ozonetherapy. Eur Rev Med Pharmacol Sci. 2012; 16(12): 1741–1747. indexed in Pubmed: 23161050.
- Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009; 67(5 Suppl): 96–106.
- Freiberger JJ, Padilla-Burgos R, McGraw T, et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. J Oral Maxillofac Surg. 2012; 70(7): 1573–1583.
- Vescovi P, Meleti M, Merigo E, et al. Case series of 589 tooth extractions in patients under bisphosphonates therapy. Proposal of a clinical protocol supported by Nd:YAG low-level laser therapy. Med Oral Patol Oral Cir Bucal. 2013; 18(4): e680–e685.
- Lopez-Jornet P, Sanchez Perez A, Amaral Mendes R, et al. Medication-related osteonecrosis of the jaw: Is autologous platelet concentrate application effective for prevention and treatment? A systematic review. J Craniomaxillofac Surg. 2016; 44(8): 1067–1072.
